Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2

after COVID-19

Authors:, Jim Boonyaratanakornkit[1,2,3*†], Chihiro Morishima[4†], Stacy Selke[4], Danniel Zamora[1,2],

Sarah McGuffin[1], Adrienne E. Shapiro[1,5], Victoria L. Campbell[1], Christopher L. McClurkan[1],

Lichen Jing[1], Robin Gross[6], Janie Liang[6], Elena Postnikova[6], Steven Mazur[6], Anu Chaudhary[4],

Marie K. Das[4], Susan L. Fink[4], Andrew Bryan[4], Alex L. Greninger[4], Keith R. Jerome [2,4], Michael

R. Holbrook[6], Terry B. Gernsheimer[1,3], Mark H. Wener[1,4], Anna Wald[1,2,7†], David M.

Koelle[1,2,4,5,8*†]

Affiliations:

[1]Department of Medicine, University of Washington, Seattle, WA 98195, USA

[2]Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

[3]Seattle Cancer Care Alliance, Seattle, WA 91809, USA

[4]Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA

98195, USA

[5]Department of Global Health, University of Washington, Seattle, WA 98195, USA

[6]Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and

Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA

[7]Department of Epidemiology, University of Washington, Seattle, WA 98195, USA

[8]Benaroya Research Institute, Seattle, WA 98101, USA

[†]These authors contributed equally.

*Address for correspondence:

Jim Boonyaratanakornkit

Fred Hutchinson Cancer Research Center

1100 Fairview Ave N, Mail Stop E5-320

Seattle, WA 98109

1 206 667 2379

Email: jboonyar@fredhutch.org

or

David Koelle

University of Washington

750 Republican Street Room E651

Seattle, WA 98109 USA

1 206 616 1940

Email: dkoelle@medicine.washington.edu

Running head: Antibody responses after COVID-19

Type: Research article

Word count abstract: 249

Word count main text: 3,835

References: 29

ABBREVIATIONS

DMSO   dimethylsulfoxide

PCR   polymerase chain reaction

EDTA   ethylenediamine tetra-acetic acid

SARS-CoV-2   severe adult respiratory syndrome coronavirus 2

COVID-19   coronavirus disease 2019

OR   odds ratio

CI   confidence interval

IgG   immunoglobulin G

BSL-3   biosafety level 3

nAb   neutralizing antibody

ROC   receiver operating curve

S1   spike protein domain 1

NP   nucleoprotein

PBMC   peripheral blood mononuclear cells

ACE2   angiotensin converting enzyme 2

CE   Conformité Européenne

ELISA   enzyme linked immune sorbent assay

ODR   optical density ratio

FRNA   fluorescence reduction neutralization assay

ABSTRACT

Background: SARS-CoV-2-specific antibodies may protect from reinfection and disease,

providing the rationale for administration of plasma containing SARS-CoV-2 neutralizing

antibodies (nAb) as a treatment for COVID-19. The clinical factors and laboratory assays to

streamline plasma donor selection, and the durability of nAb responses, are incompletely

understood. **Methods:** Adults with virologically-documented SARS-CoV-2 infection in a

convalescent plasma donor screening program were tested for serum IgG to SARS-CoV-2 spike

protein S1 domain, nucleoprotein (NP), and for nAb. **Results:** Amongst 250 consecutive persons

studied a median of 67 days since symptom onset, 243/250 (97%) were seropositive on one or

more assays. Sixty percent of donors had nAb titers ≥1:80. Correlates of higher nAb titer

included older age (adjusted OR [AOR] 1.03/year of age, 95% CI 1.00-1.06), male sex (AOR

2.08, 95% CI 1.13-3.82), fever during acute illness (AOR 2.73, 95% CI 1.25-5.97), and disease

severity represented by hospitalization (AOR 6.59, 95% CI 1.32-32.96). Receiver operating

characteristic (ROC) analyses of anti-S1 and anti-NP antibody results yielded cutoffs that

corresponded well with nAb titers, with the anti-S1 assay being slightly more predictive. NAb

titers declined in 37 of 41 paired specimens collected a median of 98 days (range, 77-120) apart

($P<0.001$). Seven individuals (2.8%) were persistently seronegative and lacked T cell responses.

Conclusions: Nab titers correlated with COVID-19 severity, age, and sex. Standard

commercially available SARS-CoV-2 IgG results can serve as useful surrogates for nAb testing.

Functional nAb levels were found to decline and a small proportion of COVID-19 survivors lack

adaptive immune responses.

INTRODUCTION

Since its emergence in late 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has spread globally, with devastating effects in many communities. At this time, no vaccines or therapeutics for the prevention or treatment of SARS-CoV-2 infection have been approved by the Food and Drug Administration (FDA). Passive immunotherapy with convalescent plasma, hyperimmune gamma globulin, or monoclonal antibodies is beneficial for treatment or prophylaxis of several infections[1], and these approaches are under investigation in patients with COVID-19. Both single donor and pooled immunoglobulin products currently prioritize collection of convalescent donor plasma with high levels of neutralizing antibodies (nAb).

NAb assays are challenging to perform and have biosafety concerns. A better understanding of the predictors and correlates of high nAb titers could be useful for improving access to high quality therapeutic plasma products. In addition, it is uncertain how durable acquired immunity will be in response to SARS-CoV-2 infection. Protection from several other respiratory viruses after natural infection is temporary and incomplete[2, 3] and longitudinal information concerning nAb levels may assist modeling the future of the outbreak until effective vaccines become widely used. We evaluated antibody levels in candidate plasma donors recovered from virologically-documented SARS-CoV-2 infection and examined the trajectory of antibody levels in a subset of donors over time. Further, we compared nAb titers with two rapid commercially available assays to determine whether these assays could substitute for time- and labor-intensive nAb measurements that require a BSL-3 facility.

RESULTS

Participant characteristics

We enrolled 250 consecutive persons interested in convalescent plasma donation with a median age of 51 years (range 19-91); 48% were men (**Table 1**). The median duration of COVID-19 symptoms was 15 days (range 0-49), and the median number of days between positive PCR testing and initial antibody testing was 61 days (range 14-112). Eighteen (11%) of participants reported hospitalization including 9 (4%) who received ICU-level care. The most common symptoms reported were fatigue (86%), fever (74%), muscle aches (73%), cough (72%), anosmia/ageusia (61%), and headache (60%) (**Supplemental Figure 1A**). The most commonly reported underlying comorbidities were lung disease (14.4%), heart disease (13.6%), hypertension (12.8%), cancer (12.8%), hyperlipidemia (9.6%), and diabetes (9.6%) (**Supplemental Figure 1B**).

Clinical correlates of neutralizing antibody response

Among the 250 participants, 12.8% had nAb titers below 1:40, 27.6% had titers of 1:40, 34.4% had titers of 1:80, and 25.2% had titers of 1:160 or greater (**Figure 1**). Next, we examined the clinical correlates of nAb titers of 1:80 or greater, as this group was eligible for donation to a pooled immunoglobulin product protocol. In a univariable analysis, older age (OR 1.04 per year, 95% CI 1.02-1.06), male sex (OR 2.27, 95% CI 1.35-3.82), the presence of fever (OR 3.12, 95% CI 1.73-5.61) or difficulty breathing (OR 2.12, 95% CI 1.26-3.54) during the acute illness episode, hospitalization denoting more severe disease (OR 9.98, 95% CI 2.31-43.16), and having diabetes (OR 5.36, 95% CI 1.55-18.48) were significantly associated with higher nAb titers (**Table 2**). In a multivariable analysis, older age (adjusted OR [AOR] 1.03 [95% CI 1.00-1.06]),

male sex (AOR 2.08 [95% CI 1.13-3.82]), the presence of fever during the acute illness episode

(AOR 2.73 [95% CI 1.25-5.97]), and hospitalization (AOR 6.59 [CI 1.32-32.96]) remained

significantly associated with higher nAb titers (**Table 2**). A longer interval in time between the

diagnostic PCR and antibody testing was also associated with lower nAb titers (OR 0.97 [CI

0.96-0.99]) (**Table 2**).

Comparison of anti-SARS-CoV-2 antibody measurements

Circulating IgG antibodies against SARS-CoV-2 antigens were measured using IgG

immunoassays for anti-S1 (Euroimmun) and anti-NP (Abbott). Amongst the 250 sera analyzed at

the initial time point, 23 (9.2%) of samples were negative by the manufacturer's criteria versus

11 (4.4%) by a z-score threshold of 3.0 for the Abbott assay. For the Euroimmun assay, 20

(8.0%) were negative by a z-score threshold of 3.0 versus 30 (12.0%) by the manufacturer's

criteria. A minority of samples demonstrated discordant results (**Figure 2**); overall, 15 (6%) were

discordant for seropositivity using z-score thresholds of 3.0 versus 19 (7.6%) using

manufacturers' thresholds.

Quantitative assay results were generally concordant. Neutralizing antibody titers correlated with

z-scores from the anti-S1 Euroimmun assay (Pearson correlation of 0.49, $P<0.001$) and with the

Abbott anti-NP assay (Pearson correlation of 0.39, $P<0.001$) (**Figure 2A, B**). Z-scores of the

Euroimmun and Abbott assays also correlated with each other (Pearson correlation of 0.69,

$P<0.001$) (**Figure 2C**). Receiver operating characteristic (ROC) curves were generated to

summarize the sensitivity and specificity of the Abbott and the Euroimmun assays for detecting

nAb titers $\geq 1:40$, $\geq 1:80$ and $\geq 1:160$ (**Supplemental Figure 2**). The area under the curve (AUC)

for the Euroimmun assay was slightly greater than for the Abbott assay across all three nAb

levels.

The criteria for positivity in the binding IgG tests was subjected to further analysis focusing on

nAb cutoffs of $\geq$ 1:80 or higher. A z-score of 3.0 in the Euroimmun assay had a sensitivity of

99% and specificity of 17% for a nAb titer $\geq$ 1:80 (**Table 3 and Supplemental Figure 2B**). To

estimate optimal cutoffs, we used Youden's index(4), which indicated that at an optimized z-

score cut-off of 34.2, the Euroimmun assay had a sensitivity of 78% and specificity of 72%. A z-

score of 3.0 in the Abbott assay had a sensitivity of 100% but a specificity of only 11%. Using an

optimized z-score cut-off of 32.6, the Abbott assay had a sensitivity of 77% and specificity of

81%. Because the optimal therapeutic titer of convalescent plasma is unknown, we also

calculated the sensitivity and specificity of both IgG binding assays to predict nAb titers $\geq$ 1:160;

as expected, these z-scores were higher (**Table 3**).

Antibody titers over time after recovery from COVID-19

Lower nAb titers were associated with a longer time after symptom resolution according to our

multivariable analysis (**Table 2**). In a cross-sectional visualization of serologic data from persons

with a nAb titer of 1:40 or greater at the initial blood draw, nAb titers, anti-S1 IgG, and anti-NP

IgG levels all demonstrated trends towards lower antibody levels with increased interval between

symptoms and blood sampling (**Supplemental Figure 3**). To further investigate this initial

observation, 41 participants enrolled during April 2020 who had nAb titers of 1:40 or greater

returned for a second blood draw to examine antibody kinetics. Neutralization titers decreased

over time in all but four participants. From these data, nAb half-life was calculated at 66.2 days

(95% CI 55.5-82.5) (**Figure 3A**). A decline in anti-S1 IgG and anti-NP IgG levels over time was

also observed in 83% and 98% of participants, respectively (**Figures 3B and 3C**). Given our

observation that compression of ODRs and resultant z-scores occur at higher levels of IgG, half-

life calculations were not performed for these latter assays.

Clinical characteristics and repeat serologic results from seronegative participants

We identified seven participants who lacked circulating antibody responses by all three assays,

despite having documented SARS-CoV-2 infection. Amongst these, one had been asymptomatic

and one had been hospitalized for COVID-19 (**Table 4**). Five (71%) were women with a median

age of 48 (range 40-62). The median time between positive SARS-CoV-2 PCR and antibody

testing was 42 days (range 30-87). The previously hospitalized participant with consistently

negative antibody results across all three antibody tests had received infliximab for vasculitis one

week prior to becoming infected with H1N1 influenza, followed one week later by infection with

SARS-CoV-2. Six seronegative participants had a repeat blood draw, a median time of 43 days

(range 20-55) after the first. Serologic test results remained negative in all individuals by all

three assays (**Table 4**).

To further investigate the immune status of the seronegative individuals, we performed IFN-γ

ELISPOT using PBMCs from follow-up samples of the six persons with repeat blood draws, and

peptides from SARS-CoV-2 structural proteins. Previous work has shown that the majority of T

cell responses in COVID-19 survivors recognize these viral proteins(5). As comparators, we

tested a subset of seropositive persons and pre-2019 healthy donors. We detected robust T cell

responses in convalescent PBMCs from convalescent SARS-CoV-2-seropositive individuals,

whereas responses from SARS-CoV-2-seronegative patients were similar to healthy donors

(**Supplemental Figure 4**).

DISCUSSION

Our characterization of a large cohort of potential SARS-CoV-2 convalescent plasma donors provides several useful observations relevant to protection after natural infection or vaccination and the manufacture of antibody-based therapeutics. We found that a significant proportion (40%) of persons failed to meet a protocol-driven nAb threshold ($\geq$ 1:80) for contribution to a pooled immunoglobulin product. Clinical factors associated with higher levels of nAb, specifically male sex, older age, higher disease severity, and shorter interval from recovery, were identified; this information could streamline future donor recruitment. Repeat testing demonstrated a decline of functional nAb over time, suggesting that these clinical characteristics are most valuable when used early after recovery. We also found that anti-SARS-CoV-2 IgG results from two widely accessible and commercially available immunoassays could reliably predict high nAb titers when used relatively early after COVID-19. Test cutoffs were empirically derived that can assist in selecting donors with increased likelihood of having high nAb titers. Finally, approximately 3% of our cohort, all with documented SARS-CoV-2 infection, did not exhibit adaptive immune responses in multiple antibody and T cell assays.

Pending full approval of antiviral drugs or a preventative vaccine, much effort has focused on passive immunization for the treatment or prevention of COVID-19, ranging from single-donor plasma and pooled immunoglobulin products to recombinant antibodies(6-8). Pooled products have a track record of safety and efficacy for other pathogens including respiratory viruses(1), and are most efficiently manufactured from plasma containing higher amounts of functional antibody. While the immunoglobulin isotypes and functional activities associated with improved COVID-19 outcomes remain an active area of investigation(9), neutralization of viral entry is

thought to be a desirable attribute that corresponds to protection. Thus, qualifying plasma

donation for NIH hyperimmune globulin protocol NCT04344977 has focused on high nAb titers.

Observational data from a single donor plasma program generally support the premise that

neutralizing antibodies are desirable, with lower mortality rates noted for persons receiving

plasma containing the top quintile of anti-S binding antibodies(6). A small randomized

controlled trial also found a trend towards a shorter time to clinical improvement and lower

mortality with convalescent plasma(10). We therefore sought to identify clinical characteristics

associated with plasma neutralizing antibodies and compared two widely used SARS-CoV-2

antibody tests for ability to predict nAb titers of 1:80 or greater.

Our clinical findings of an association between higher nAb titers with male sex, older age, and

hospitalization are consistent with a recent report from another convalescent plasma candidate

donor study(11) and other reports concerning recovered individuals(12-14). The relationship

between greater infection severity, and presumably greater antigen load, with higher acquired B

cell responses is paralleled by data by others showing an association between more severe

infection with higher T cell responses in general, and, in particular, circulating CD4+ T follicular

helper (cT$_{FH}$) responses(15). T$_{FH}$ cells provide critical positive signals to antigen-specific B cells

in lymph node germinal center (GC) reactions promoting avid and long-lasting antibody

responses.

Our cross-sectional analyses also found a trend towards lower nAb titers with increased elapsed

time between antibody testing after symptom resolution. This was confirmed in longitudinal

analyses of 41participants re-evaluated approximately 3 months after their first test. A quarter of

the re-evaluated participants had nAb titers below 1:40 at the second time point, and declines in

circulating anti-S1 and anti-NP IgG levels were found in >80% of participants over the relatively

short period of time between the two blood draws. A critical and currently unresolved issue for

SARS-CoV-2 infection is the extent to which prior infection prevents or ameliorates various

characteristics of re-infection, including disease, viral shedding, and transmission potential. It is

likely that protection efficiency will vary according to clinical characteristics of the host and of

the initial infection, with time after initial infection, and with the virologic or clinical endpoint

under consideration. The issue of antibody durability has been addressed in prior cross-sectional

and longitudinal studies, obviously limited by the recency of the pandemic. Decreases in SARS-

CoV-2 nAb titers have been observed in some prior studies(13, 16, 17) but not others(18). The

decline of nAb titers over time and the low somatic hypermutation in immunoglobulin genes

recovered from SARS-CoV-2-specific memory B cells(19) both suggest that ineffective help

from T_{FH} CD4 T cells is occurring in germinal centers. While circulating T_{FH}-like SARS-CoV-2-

reactive CD4 T cells have been detected in the blood(15), autopsy data from fatal COVID-19 is

consistent with poor germinal center reactions(20). Overall, waning immunity after natural

infection raises concern for re-infection over time as observed for other respiratory viruses,

including the endemic coronaviruses(2, 3). Data on protection from re-infection with SARS-

CoV-2 are incomplete at this time, with case reports of re-infection(21) contrasting with cohort

data from an occupational outbreak in which persons with baseline SARS-CoV-2-specific

circulating antibody were protected from infection(22). Additional research will be required to

address the immunologic and clinical parameters associated with protection from re-infection

after SARS-CoV-2 infection.

With regard to test performance, we found a slightly stronger correlation between nAb titers and

anti-S1 IgG levels using the Euroimmun assay compared to anti-NP IgG levels determined using

the Abbott assay. We were able to establish cutoffs using z-scores for each assay that had good

performance for predicting nAb titers of 1:80 or greater, or 1:160 or greater, which should be

useful as the clinical efficacy of single-donor and pooled immunoglobulin products continue to

be defined. The superior performance of the anti-S1 assay is not unexpected given that

antibodies that neutralize SARS-CoV-2 bind to the S protein present on the surface of infectious

virus. This finding is also consistent with studies that have shown that the detection of NP-

binding antibodies does not always correlate with the presence of nAb(23).

In the present study, we used z-scores to standardize serologic results to the same scale and to

account for local test performance characteristics(24). Despite using a relatively conservative

positivity threshold of 3 standard deviations above our assay-specific negative control means,

these z-score positivity thresholds were lower than manufacturer-recommended thresholds for

both assays. Accordingly, a larger number of samples were considered "negative" by both assays

using manufacturer-recommended thresholds compared to z-scores. Although continuous values

are obtained and accessible for both Abbott and EU assays, it is worth noting that both are EUA-

approved as qualitative and not quantitative assays. Although the Euroimmun assay appears to be

have a wider analytic range in comparison to the Abbott assay, both assays yield results that

plateau at different thresholds. Thus, values at higher levels for both assays would require

dilution of high-titer sera to achieve linear results. However, even in the absence of re-assay after

dilution, however, we were able to discern declines in binding IgG titers over time within-

subjects, similar to our observations for nAb.

A small proportion (3%) of participants tested negative on all three antibody assays despite

SARS-CoV-2 RNA detection in previously collected respiratory specimens. Each seronegative

COVID-19 survivor tested also had low T cell responses, similar to pre-2019 healthy controls,

while seropositive subjects had abundant interferon-gamma producing cells in the blood, similar

to other reports(25). While false positive PCR results are possible, all subjects except one, who

was a household contact of a person with symptomatic and PCR-confirmed COVID-19, had a

clinical syndrome consistent with COVID-19. Asymptomatic and mildly symptomatic patients

with COVID-19 have been found to have lower antibody levels and also were more likely to

sero-revert in the early convalescent phase(14). Discordance between positive PCR and negative

circulating antibody may be related to timing of the blood draw after illness, milder symptoms

correlating with lower or briefer antigen exposure, and/or an unrecognized immune suppression.

Our study has some limitations. First, although our sample population included a clinically

diverse population with respect to age, sex, and clinical presentation, the cohort was

predominantly white. Additional studies in minority populations at risk for worse outcomes will

be needed to determine the generalizability of these results. Second, our study was mainly cross-

sectional, and longitudinal data were obtained on only a subset of the cohort. Third, in analyzing

the decline of neutralizing antibody titers, a titer of 1:20 was used as a surrogate for all titers

<1:40, since this value was the next serial 2-fold titer below the lowest positive result. We chose

this conservative surrogate value to avoid the possibility of over-estimating the rate of decline in

neutralizing antibody titers. Fourth, we focused on blood immune responses. It is possible that

the seronegative individuals in our study mounted a mucosal humoral or T cell response that

could provide protection against re-infection. Probing mucosal and T cell immunity may be

important in understanding the immune response of subjects with milder infection.

In summary, our data provide important information regarding the predictive value of clinical

factors and commercially available immunoassay results for high nAb titers. This information

could aid in streamlining the selection of potential convalescent plasma donors and increase

access to and efficiency of donor sample testing. Since transfusion of plasma with higher

antibody titers has been associated with improved outcomes(6), and since higher titer plasma is

the most suitable for the creation of pooled products, our data further suggest that plasma

donations should be sought closer to the resolution of symptoms, rather than later, to optimize

yield. A minimum level of nAb necessary for protection has not been established and it is

unknown whether persons with low titers will boost their immune responses upon re-exposure.

However, our data raise concern that functional antibodies show a quantitative decline over a

relatively short period of time after recovery in those with relatively mild infections. Further

insight into these issues is critical to monitoring herd immunity and implementation of

immunization programs.

METHODS

Study description

Seattle-area participants were recruited for potential donation of single donor plasma units

(NCT04338360), and plasma for manufacture of a pooled anti-SARS-CoV-2 product

(NCT04344977). Both studies required age 18 or greater and PCR-positivity to SARS-CoV-2;

criteria for donation for the pooled product also included a nAb titer of $\geq$ 1:80(26). Participants

provided demographic and clinical information, including positive SARS-CoV-2 results, and a

blood sample.

Serologic assays

Plasma from EDTA and heparinized blood and serum were prepared within 12 hours of

collection. Serum and plasma for IgG assays were stored at 4°C and assays performed within 72

hours of sample processing. PBMCs were isolated from heparinized blood within 12 hours of

phlebotomy using standard Ficoll-Hypaque density gradient centrifugation and cryopreserved in

liquid nitrogen in 90% fetal calf serum/10% DMSO. EDTA plasma was stored at -80°C for

neutralization assays.

Serologic testing was performed using two FDA-authorized (via Emergency Use Authorization),

CE-marked immunoassays; both are approved to provide qualitative results, although both yield

quantitative values. The anti-SARS-CoV-2 IgG ELISA from Euroimmun (Lubeck, Germany)

measures antibodies to recombinant spike protein (S1 domain), containing the receptor binding

domain that interacts with ACE2(27). All testing and analyses were performed according to the

manufacturer's protocols, with the OD ratio (ODR) calculated using the kit calibrator. The

manufacturer-provided reference range is as follows: ratio <0.8 (negative), ratio $\geq$ 0.8 to <1.1

(borderline), and ratio $\geq$ 1.1 (positive). The Abbott SARS-CoV-2 IgG chemiluminescent

microparticle immunoassay (Abbott ARCHITECT, Abbott Park, IL, USA) measuring antibodies

to the SARS-CoV-2 nucleoprotein (NP) was performed per the manufacturer's instructions.

Equivalent to an ODR, the kit calibrator was used to establish the assay index result. Index

values $\geq$ 1.4 are considered positive by the manufacturer.

To standardize results and facilitate comparisons, ODR scores for each sample were converted to

z-scores (number of SDs above the negative control mean) as follows: z-score = (Test ODR –

Mean negative control ODR) / Mean negative control standard deviation (SD)(24). Negative

control sera had been collected between 2015 and 2019 from healthy community blood donors

and from patients tested in the clinical laboratory by western blot for potential HSV infection

(N=78 for Euroimmun and N=136 for Abbott). ODR were converted to z-scores as follows: For

Euroimmun, z-score = (ODR – 0.26)/0.13 and for Abbott, z-score = (index result – 0.08)/0.14).

A conservative z-score $\geq$ 3 was considered positive to minimize false positive results.

Neutralizing antibody titers were performed using a fluorescence reduction neutralization assay

(FRNA) with authentic SARS-CoV-2 (2019-nCoV/USA-WA1-A12/2020 from the US Centers

for Disease Control and Prevention, Atlanta, GA, USA) at the NIH-NIAID Integrated Research

Facility at Fort Detrick, MD, USA. In these experiments, a fixed volume of diluted virus was

incubated with an equivalent volume of test plasma for 1 hour at 37 °C prior to adding the

suspension to Vero E6 cells (ATCC, Manassas, VA, USA, #CRL-1586). The virus was allowed

to propagate for 24 hours prior to fixing the cells. Following fixation, the cells were

permeabilized and probed with a SARS-CoV-2 nucleoprotein-specific rabbit primary antibody

(Sino Biological, Wayne, PA, USA, #40143-R001) followed by an Alexa594-conjugated

secondary antibody (Life Technologies, San Diego, CA, USA, #A11037). The total number of

infected cells in four fields per well with each field containing at least 1000 cells was quantified

using an Operetta high content imaging system (Perkin Elmer, Waltham, MA, USA). Plasma

was tested using two-fold serial dilutions from 1:40 to 1:1280 with four replicates per dilution.

Results are reported as the highest dilution of plasma leading to at least 50% reduction of SARS-

CoV-2 titers. Each assay was controlled with internal addition of an S-specific neutralizing

polyclonal antibodies. If a 1:40 dilution did not lead to at least 50% reduction of viral titer,

results were reported as <1:40 even though some inhibition of virus propagation may have been

present. To enable analysis of nAb kinetics over time, a value of 1:20 was used as a surrogate for

results <1:40 since this value was the next serial 2-fold titer below the lowest positive result.

T cell assays

To measure T cell responses to SARS-CoV-2, PBMCs were thawed and plated at 2.5-3 X 10^5

cells/well in duplicate. Stimuli were 9 pools of SARS-CoV-2 peptides (Genscript, Piscataway,

NJ, USA) corresponding to the S, membrane (M), and NP proteins of SARS-CoV-2 strain

Wuhan (Genbank MN908947.3) in pools of 50-56 peptides/pool. Peptides 13 amino acids long

and overlapping by 9 amino acids were used at a final concentration of 1 µg/mL for each peptide

and 0.2% DMSO. Negative control was 0.2% DMSO; positive control was 1.6 µg/mL

phytohemagglutinin (PHA-P, Remel, Lenexa, KS, USA). Interferon-gamma (IFN-γ) ELISPOT

was performed as described(28). All subjects appropriately had too-numerous-to-count positive

responses to PHA. Results are reported as spot-forming units/10^6 PBMCs for the background-

subtracted response to SARS-CoV-2 peptide pools.

Statistics

Univariable analysis was performed using a t-test for continuous variables and Chi-square test

for categorical variables. Variables with $P \leq 0.2$ in univariable analysis were candidates for

multivariable models using logistic regression and were retained in the models if they remained

significant or substantially modified the effect of another factor. Statistical significance was

defined as two-sided $P<0.05$. The sensitivity and specificity for high nAb titers by the Abbott

and the Euroimmun assays were plotted by generating a receiver operating characteristic (ROC)

curve. SPSS software (IBM, Chicago, IL, USA) was used for statistical analysis and to generate

ROC curves, the latter with default parameters. Youden's index was calculated for all points of

the ROC curves, and the maximum index value was used to select the optimal z-score cut-off(4).

Longitudinal analysis of nAb levels was performed using linear mixed effects models with the R

package *lme4*(29).

Study approval

Institutional Review Board approval was obtained from the University of Washington and all

participants underwent informed consent form.

AUTHOR CONTRIBUTIONS

J.B., C.M., M.K.D., D.M.K, and A.W. wrote the manuscript with input from all co-authors. A.W. and T.B.G. conceived the study. J.B. and A.W. wrote the IRB protocol. J.B., D. Z., S. McGuffin, and A.E.S., recruited participants. S.S. managed the data. V.L.C., C.L.M., and D.M.K. processed specimens. C.M., A.C., M.K.D., A.G., K.R.J., S.L.F., L.J., C.L.M., and M.W. characterized and performed antibody and ELISPOT immunoassays. M.H., R.G., J.L., E.P., and S.M. performed the neutralization assays. J.B., C.M., S.S., M.W., A.W., and D.M.K. performed statistical analysis and generated tables and figures. The order of the first author is alphabetical.

ACKNOWLEDGMENTS

We are grateful to all study participants. We thank Angela LeClair, Miko Robertson, Mark Drummond, Kirsten Hauge, Isabelle Hwang, Kristina Chaffee, Avery Forrow, and Tanvi Aggarwal for support in recruiting and enrolling subjects. We thank the members of the University of Washington Clinical Immunology and Virology Labs for conducting the serological testing.

FUNDING

The project was funded in part by the Frederick National Laboratory for Cancer Research with support from the National Institute for Allergies and Infectious Diseases (NIAID) under Contract No. 75N91019D00024. This work was also supported by the Fred Hutchinson Joel Meyer's Endowment (J.B.), Fast-Grants (J.B.), a new investigator award from the American Society for Transplantation and Cell Therapy (J.B.), NIH contract 75N93019C0063 (D.M.K), NIH T32-

457   **COMPETING INTERESTS**

458   A.L.G. reports consulting fees from Abbott Molecular, outside of the submitted work.

459   **REFERENCES**
460
1.   Casadevall A, and Pirofski LA. The convalescent sera option for containing COVID-19. *J*

Clin Invest. 2020;130(4):1545-8.

2.   Boonyaratanakornkit J, Englund JA, Magaret AS, Bu Y, Tielsch JM, Khatry SK, et al.

Primary and Repeated Respiratory Viral Infections Among Infants in Rural Nepal. *J*

Pediatric Infect Dis Soc. 2020;9(1):21-9.

3.   Kiyuka PK, Agoti CN, Munywoki PK, Njeru R, Bett A, Otieno JR, et al. Human

Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal

Kenya. *J Infect Dis.* 2018;217(11):1728-39.

4.   Youden WJ. Index for rating diagnostic tests. *Cancer.* 1950;3(1):32-5.

5.   Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al.

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute

respiratory distress syndrome. *Sci Immunol.* 2020;5(48).

6.   Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of

Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial

Three-Month Experience. *medRxiv.* 2020.

7.   Kreye J, Reincke SM, Kornau HC, Sanchez-Sendin E, Corman VM, Liu H, et al. A SARS-

CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model.

bioRxiv : the preprint server for biology. 2020.

8.   Focosi D, Anderson AO, Tang JW, and Tuccori M. Convalescent Plasma Therapy for

COVID-19: State of the Art. *Clin Microbiol Rev.* 2020;33(4).

9.   Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct Early

Serological Signatures Track with SARS-CoV-2 Survival. *Immunity.* 2020.

10.   Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma

484   Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening

485   COVID-19: A Randomized Clinical Trial. *JAMA.* 2020;324(5):460-70.

486   11.   Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, et al. Sex, age, and

487   hospitalization drive antibody responses in a COVID-19 convalescent plasma donor

488   population. *J Clin Invest.* 2020.

489   12.   Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al.

490   Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med.* 2020.

491   13.   Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-

492   2 in patients of novel coronavirus disease 2019. *Clin Infect Dis.* 2020.

493   14.   Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological

494   assessment of asymptomatic SARS-CoV-2 infections. *Nat Med.* 2020;26(8):1200-4.

495   15.   Meckiff BJ, Ramirez-Suastegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, et al. Single-

496   Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 (+) T Cells. *SSRN.*

497   2020:3641939.

498   16.   Wang K, Long QX, Deng HJ, Hu J, Gao QZ, Zhang GJ, et al. Longitudinal dynamics of

499   the neutralizing antibody response to SARS-CoV-2 infection. *Clin Infect Dis.* 2020.

500   17.   Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al.

501   Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl J*

502   *Med.* 2020.

503   18.   Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PM, Thouvenel C, et al. Functional

504   SARS-CoV-2-specific immune memory persists after mild COVID-19. *medRxiv.*

505   2020:2020.08.11.20171843.

19. Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, et al. Longitudinal
Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-
19 Patients. *Cell.* 2020;182(4):843-54.e12.
20. Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. Loss of
Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. *Cell.*
2020.
21. To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a
phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome
sequencing. *Clin Infect Dis.* 2020.
22. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al.
Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a
fishery vessel outbreak with high attack rate. *J Clin Microbiol.* 2020.
23. McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, et al.
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and
nucleocapsid with implications on COVID-19 immunity. *JCI Insight.* 2020.
24. Das MK, Chaudhary A, Bryan A, Wener MH, Fink SL, and Morishima C. Rapid Screening
Evaluation of SARS-CoV-2 IgG Assays Using Z-Scores to Standardize Results. *Emerg
Infect Dis.* 2020;26(10).
25. Kroemer M, Spehner L, Vettoretti L, Bouard A, Eberst G, Floury SP, et al. COVID-19
patients display distinct SARS-CoV-2 specific T-cell responses according to disease
severity. *J Infect.* 2020.
26. US Food and Drug Administration. Investigational COVID-19 Convalescent Plasma
(FDA-2020-D-1137). *Center for Biologics Evaluation and Research.* May

2020:https://www.fda.gov/regulatory-information/search-fda-guidance-

documents/investigational-covid-19-convalescent-plasma.

27. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM

structure of the 2019-nCoV spike in the prefusion conformation. *Science.*

2020;367(6483):1260-3.

28. Ott M, Jing L, Lorenzo L, Casanova JL, Zhang SY, and Koelle DM. T-Cell Responses to

HSV-1 in Persons Who Have Survived Childhood Herpes Simplex Encephalitis. *Pediatr*

Infect Dis J. 2017.

29. Bates DM, Machler M, Bolker BM, and Walker SC. lme4: Linear Mixed-Effects Models

Using Eigen and S4. R Package Version 1.1-7. *Journal of Statistical Software.*

2015;67(1):1-48.

FIGURES

Figure 1. Distribution of neutralization antibody titers in convalescent subjects (N=250). Values

on the x-axis represent the dilution factor of serum that yielded a 50% reduction in SARS-CoV-2

infection of Vero E6 cells.

Figure 2. Relationship between serum measurements of anti-SARS-CoV-2 antibodies. Levels of anti-SARS-CoV-2 IgG antibodies specific for S1(Euroimmun, EU) (A) or of anti-SARS-CoV-2 IgG antibodies specific for NP (Abbott) expressed as z-scores (B) are shown relative to neutralizing antibody titers obtained from the same samples. Each symbol represents the initial specimen from one person. (C) Anti-SARS-CoV-2 S1 IgG levels (EU) relative to anti-SARS-CoV-2 nucleocapsid (N) protein IgG levels (Abbott). The dotted lines indicate the positivity threshold (z-score of 3) for both EU and Abbott assay results. Colored circles indicate discordant results between the Euroimmun and Abbott assays. Blue circles represent samples with negative z-score results (z-score <3.0) by Euroimmun and positive (z-score ≥3.0) by Abbott. Conversely, red circles represent samples with positive (z-score ≥3.0) results by Euroimmun and negative (z-score <3.0) by Abbott.

559
560
561 **Figure 3.** Individual antibody levels obtained at various timepoints after symptom resolution

562 from 41 persons recovered from PCR-positive SARS-CoV-2 infection and an initial nAb titer of

563 1:40 or greater. The same 41 persons are represented in each graph. (A) Neutralization assay, (B)

564 Euroimmun (anti-S1) IgG assay, (C) Abbott (anti-NP) IgG assay results as a function of time

565 since resolution of symptoms. Each line connects two results from a single participant.

    TABLES

    Table 1. Demographic and clinical characteristics of study subjects.

Category	Value (N=250)
Age (range)	51 (19-91)
Men	119 (47.6%)
Hispanic ethnicity	11 (4.4%)
Race	
White	214 (85.6)
Asian	22 (8.8%)
Black	4 (1.6%)
Pacific Islander	1 (0.4%)
Native American	1 (0.4%)
Other	4 (1.6%)
More than one race	4 (1.6%)
Median (range) days between symptom resolution and antibody test[A]	50 (21-110)
Median (range) days between positive PCR and antibody test	61 (14-112)
Severity	
Outpatient[B]	223 (89.2%)
Hospitalized but not in ICU	18 (7.2%)
ICU	9 (3.6%)

    [A]Excluding one asymptomatic person

571   [B]Includes one asymptomatic participant who was a household contact of a person with

572   symptomatic COVID-19

573 Table 2. Clinical correlates of high (≥1:80) circulating SARS-CoV-2 neutralizing antibody
574 titers.

Co-variates	Univariable		Multivariable	
	Odds Ratio (OR)	95% Confidence Interval (CI)	Adjusted Odds Ratio (AOR)	95% Confidence Interval (CI)
Age, per year	**1.04**	1.02-1.06	**1.03**	1.00-1.06
Men vs women	**2.27**	1.35-3.82	**2.08**	1.13-3.82
Race, white vs non-white	0.52	0.24-1.13		
Symptoms				
Fever	**3.12**	1.73-5.61	**2.73**	1.25-5.97
Cough	**1.52**	0.87-2.67	0.94	0.45-1.97
Runny nose	0.97	0.57-1.65		
Difficulty breathing	**2.12**	1.26-3.54	1.65	0.84-3.25
Wheezing	1.34	0.71-2.55		
Sore throat	**0.63**	0.37-1.07	0.80	0.41-1.58
Diarrhea	0.83	0.49-1.40		
Fatigue	0.86	0.41-1.80		
Muscle aches	1.23	0.69-2.17		
Anosmia/ageusia	0.77	0.45-1.30		
Headache	0.99	0.59-1.67		
Number of symptoms	1.07	0.95-1.21	1.08	0.86-1.34

Days between positive PCR and antibody test	**0.98**	0.97-0.99	**0.97**	0.96-0.99
Duration of symptoms (days)^A	1.00	0.98-1.03		
Hospitalization	**9.98**	2.31-43.16	**6.59**	1.32-32.96
Comorbidities				
Cancer	**2.23**	0.96-5.19	2.27	0.81-6.38
Heart disease	1.49	0.69-3.22		
Kidney disease	0.78	0.25-2.39		
Hypertension	1.34	0.62-2.92		
Hyperlipidemia	1.73	0.69-4.34		
Lung disease	0.72	0.36-1.47		
Diabetes	**5.36**	1.55-18.48	2.75	0.69-10.95

576 ^{A}excluding one asymptomatic subject

577 **Bolded** odds ratios indicate *P*<0.2 in the univariable analysis or *P*<0.05 in the multivariable

578 analysis.

Table 3. Sensitivity and specificity of circulating IgG anti-S1 and anti-NP immunoassays for predicting neutralizing antibody titers.

Criteria	nAb ≥ 1:80				nAb ≥ 1:160			
	Z-score	ODR	Sensitivity	Specificity	Z-score	ODR	Sensitivity	Specificity
Manufacturer's cut-off[A]								
Anti-S1 IgG	4.2	0.8	0.99	0.24	4.6	0.8	1.00	0.14
Anti-NP IgG	9.4	1.4	0.99	0.21	8.4	1.4	1.00	0.12
Z-score cut-off of 3.0								
Anti-S1 IgG	3.0	0.7	0.99	0.17	3.0	0.6	1.00	0.11
Anti-NP IgG	3.0	0.5	1.00	0.11	3.0	0.5	1.00	0.06
Optimized Z-score[B]								
Anti-S1 IgG	32.6	4.5	0.77	0.81	42.4	5.8	0.87	0.74
Anti-NP IgG	34.2	4.9	0.78	0.72	40.0	5.7	0.86	0.72

[A]Z-scores calculated for manufacturer-determined optical density ratio (ODR) positivity thresholds of 0.8 for anti-S1 IgG and 1.4 for anti-NP IgG immunoassays.

[B]Optimal Z-score based on the maximum value of Youden's index.

Table 4. Clinical and laboratory characteristics of seronegative individuals.

Subject	Age at draw[A]	Sex	Severity	Comorbidities	Days sx onset to 1st draw	Days (+) PCR to 1st draw	Days symptom resolved to 1st draw	Days between 1st and 2nd draws
1	40s	M	Outpt	None	41	38	30	54
2	40s	M	Outpt	None	43	39	28	55
3	60s	F	Outpt	None	47	41	37	46
4	40s	F	Outpt	None	42	42	22	41
5	40s[B]	F	Outpt	Asthma	52	50	40	na
6	40s	F	Inpt	Lung carcinoid; Asthma; Vasculitis	95	87	70	20
7	50s	F	Outpt	None	78	76	64	21

Abbreviations: Outpt for outpatient; Inpt for inpatient; Asx for asymptomatic; sx for symptoms;

na for non-applicable

[A]Ages are given as decade of life

[B]Subject did not return for a second blood draw